Writing an introduction about this topic: TNFR II for cancer diagnosis and prognosis. Use this heading: Tumour necrosis factor (TNF) receptor 2: TNFR2 expression is found in cancer cells: Increased TNFR2 expression was observed in immunosuppressive cells in cancers: Increased circulating soluble TNFR 2 has been observed in chronic diseases such as cancer: TNFR2 induces progression and compromise immune response against cancer: Here are some sources you can use if you wish: 1. Vanamee S, Faustman DL. TNFR2: A Novel Target for Cancer Immunotherapy. Trends in Molecular Medicine. 2017;23(11):1037-46. 2. Chen X, Plebanski M. Editorial: The Role of TNF-TNFR2 Signal in Immunosuppressive Cells and Its Therapeutic Implications. Frontiers in Immunology. 2019;10(2126). 3. Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clinical Immunology. 2013;149(1):97-110. 4. Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M. Lenalidomide?based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. American journal of hematology. 2014;89(8):795-802. 5. Yan F, Du R, Wei F, Zhao H, Yu J, Wang C, et al. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunology, Immunotherapy. 2015;64(11):1475-85. 6. Chen X, Subleski JJ, Kopf H, Howard OM, Mnnel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180(10):6467-71. 7. Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. Journal of molecular medicine (Berlin, Germany). 2016;94(5):509-22. 8. Sheng Y, Li F, Qin Z. TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors. Frontiers in Immunology. 2018;9(1170). 9. Al-Hatamleh MAI, . ENS, Boer JC, Ferji K, Six J-L, Chen X, et al. Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation InhibitorAn Opportunity for Cancer Treatment. Cells. 2020;9(1):33. 10. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87(8):3127-31. 11. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nature reviews Drug discovery. 2013;12(2):147-68. 12. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Journal of Clinical Oncology. 1997;15(2):499-508. 13. Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells. Front Immunol. 2017;8:1482.Show more
